MCID: PST095
MIFTS: 52

Post-Thrombotic Syndrome

Categories: Cardiovascular diseases, Blood diseases

Aliases & Classifications for Post-Thrombotic Syndrome

MalaCards integrated aliases for Post-Thrombotic Syndrome:

Name: Post-Thrombotic Syndrome 12 14
Postphlebitic Syndrome 12 51 41 69
Postphlebetic Syndrome with Ulcer and Inflammation 12
Postphlebetic Syndrome with Inflammation 12
Postphlebetic Syndrome with Ulcer 12
Postthrombotic Syndrome 69
Venous Stress Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2364
ICD10 32 I87.0
MeSH 41 D011186

Summaries for Post-Thrombotic Syndrome

Disease Ontology : 12 A venous insufficiency that is characterized by aching pain, heaviness, swelling, cramps, itching, or tingling in the affected limb and is a chronic complication of deep venous thrombosis.

MalaCards based summary : Post-Thrombotic Syndrome, also known as postphlebitic syndrome, is related to chronic venous insufficiency and thrombosis. An important gene associated with Post-Thrombotic Syndrome is F5 (Coagulation Factor V), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Toll-Like receptor Signaling Pathways. The drugs Dalteparin and Heparin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 72 Post-thrombotic syndrome (PTS), also called postphlebitic syndrome and venous stress disorder is a... more...

Related Diseases for Post-Thrombotic Syndrome

Diseases related to Post-Thrombotic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 chronic venous insufficiency 31.9 ICAM1 SERPINE1
2 thrombosis 29.9 F2 F5 SERPINC1 SERPINE1
3 venous insufficiency 29.6 F2 ICAM1 SERPINE1
4 thrombophilia due to thrombin defect 29.4 F2 F5 F8 SERPINC1 SERPINE1
5 pulmonary hypertension 29.1 IL6 SERPINC1 SERPINE1
6 thrombophilia 28.9 F2 F5 F8 SERPINC1 SERPINE1
7 vascular disease 28.4 CCL2 F5 SERPINC1 SERPINE1
8 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 10.5
9 multicentric castleman disease 10.4 F8 IL6
10 acquired hemophilia a 10.4 F5 F8
11 acquired hemophilia 10.4 F5 F8
12 factor v and factor viii, combined deficiency of, 2 10.4 F5 F8
13 chronic eosinophilic pneumonia 10.4 ICAM1 IL6
14 hypersensitivity reaction type iii disease 10.4 ICAM1 IL6
15 macular retinal edema 10.4 ICAM1 IL6
16 carotid artery occlusion 10.4 F5 F8
17 eye lymphoma 10.4 IL6 TLR9
18 hemophilia a 10.4 F5 F8
19 viral pneumonia 10.3 IL6 TLR9
20 arteriosclerosis obliterans 10.3 ICAM1 IL6
21 central nervous system vasculitis 10.3 IL6 TLR9
22 cytomegalovirus infection 10.3 ICAM1 IL6
23 von willebrand disease, type 1 10.3 F2 F8
24 alcohol-related birth defect 10.3 F2 F8
25 vitamin k deficiency hemorrhagic disease 10.3 F2 F8
26 immune-complex glomerulonephritis 10.3 ICAM1 TLR9
27 cardiac tamponade 10.3 F2 F8
28 plasmodium vivax malaria 10.3 ICAM1 IL6
29 nodular goiter 10.3 ICAM1 IL6
30 paracetamol poisoning 10.3 F2 F5
31 compartment syndrome 10.3 F2 F8
32 hemophilia 10.3 F2 F8
33 cerebral sinovenous thrombosis 10.3 F2 F5
34 hemoglobin e disease 10.3 F2 F5
35 lichen disease 10.3 ICAM1 TLR9
36 porencephaly 10.3 F2 F5
37 nonalcoholic steatohepatitis 10.2 F2 IL6
38 lacrimal apparatus disease 10.2 IL6 TLR9
39 intermediate coronary syndrome 10.2 IL6 SERPINC1
40 perinatal necrotizing enterocolitis 10.2 IL6 TLR9
41 factor xii deficiency 10.2 F5 SERPINC1
42 acute respiratory distress syndrome 10.2 F5 IL6
43 inferior vena cava interruption 10.2 F5 SERPINE1
44 amaurosis fugax 10.2 F5 SERPINE1
45 scott syndrome 10.2 F2 F5
46 intestinal impaction 10.2 F2 SERPINC1
47 blood protein disease 10.2 F2 SERPINC1
48 leech infestation 10.2 F2 SERPINC1
49 alpha-2-plasmin inhibitor deficiency 10.2 F2 SERPINC1
50 catastrophic antiphospholipid syndrome 10.2 F5 SERPINE1

Comorbidity relations with Post-Thrombotic Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease
Hypertension, Essential Ischemic Heart Disease
Peripheral Vascular Disease Venous Insufficiency

Graphical network of the top 20 diseases related to Post-Thrombotic Syndrome:



Diseases related to Post-Thrombotic Syndrome

Symptoms & Phenotypes for Post-Thrombotic Syndrome

MGI Mouse Phenotypes related to Post-Thrombotic Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.8 IL6 SERPINC1 SERPINE1 TLR9 F2 F8
2 homeostasis/metabolism MP:0005376 9.76 IL6 SERPINC1 SERPINE1 TLR9 F2 F5
3 immune system MP:0005387 9.56 SERPINC1 SERPINE1 TLR9 CCL2 F2 F8
4 mortality/aging MP:0010768 9.23 IL6 SERPINC1 SERPINE1 TLR9 F2 F5

Drugs & Therapeutics for Post-Thrombotic Syndrome

Drugs for Post-Thrombotic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4,Phase 3 9005-49-6
2
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6 46507594 772
3
Rivaroxaban Approved Phase 4 366789-02-8
4
Glucosamine Approved, Investigational, Nutraceutical Phase 4,Early Phase 1 3416-24-8 439213
5 Anticoagulants Phase 4,Phase 3,Phase 1,Phase 2
6 calcium heparin Phase 4,Phase 3
7 Fibrinolytic Agents Phase 4,Phase 3
8 Heparin, Low-Molecular-Weight Phase 4,Phase 3
9 Anesthetics Phase 4,Phase 2
10 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
11 Antithrombin III Phase 4,Phase 3
12 Antithrombins Phase 4,Phase 3
13 Factor Xa Inhibitors Phase 4,Phase 3
14 HIV Protease Inhibitors Phase 4,Phase 3
15
protease inhibitors Phase 4,Phase 3
16 Serine Proteinase Inhibitors Phase 4,Phase 3
17 Antimetabolites Phase 4,Phase 1,Phase 2
18 Hypolipidemic Agents Phase 4,Phase 1,Phase 2
19 Lipid Regulating Agents Phase 4,Phase 1,Phase 2
20 Glucuronyl glucosamine glycan sulfate Phase 4
21 Hypoglycemic Agents Phase 4
22 serine Nutraceutical Phase 4,Phase 3
23 Nadroparin Approved, Investigational Phase 3 9041-08-1
24
Warfarin Approved Phase 3,Phase 1,Phase 2 81-81-2 54678486 6691
25
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
26
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
27
Thrombin Approved, Investigational Phase 3,Phase 2
28
Tenecteplase Approved Phase 3 191588-94-0
29 tannic acid Approved, Nutraceutical Phase 3
30 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
31
Menadione Approved, Nutraceutical Phase 3 58-27-5 4055
32
Phytonadione Approved, Investigational, Nutraceutical Phase 3 84-80-0 5284607 4812
33 Calcium, Dietary Phase 3,Phase 2,Phase 1
34 Plasminogen Phase 3
35 Tissue Plasminogen Activator Phase 3
36 Coagulants Phase 3
37 Hemostatics Phase 3
38 Vitamins Phase 3,Phase 2
39 Antibodies Phase 3
40 Antibodies, Antiphospholipid Phase 3
41 Immunoglobulins Phase 3
42 Dabigatran Phase 3
43 Menaquinone Nutraceutical Phase 3
44 naphthoquinone Nutraceutical Phase 3
45 Vitamin K Nutraceutical Phase 3
46
Nitric Oxide Approved Phase 2 10102-43-9 145068
47
Methyl salicylate Approved, Vet_approved Phase 2 119-36-8 4133
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
Pyridoxal Approved, Nutraceutical Phase 2 66-72-8 1050
50
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054

Interventional clinical trials:

(show top 50) (show all 147)

# Name Status NCT ID Phase Drugs
1 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
2 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Unknown status NCT01252420 Phase 4 Enoxaparin
3 Practicability of Gliding Aids for Medical Compression Stockings Completed NCT01432795 Phase 4
4 OASIS Wound Matrix (Oasis) Mechanism of Action Completed NCT00570141 Phase 4
5 DermACELL in Subjects With Chronic Wounds of the Lower Extremities Completed NCT01970163 Phase 4
6 Wound Fluid Protease Levels During Use of Novel Wound Dressing Completed NCT01567150 Phase 4
7 Skin Ulcers Treatment With an Handicraft Topical Device Completed NCT02512159 Phase 4
8 Rivaroxaban With Diosmine in Long-term Treatment of DVT Recruiting NCT03413618 Phase 4 Rivaroxaban;Diosmin
9 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Recruiting NCT02959801 Phase 4
10 Juxta-CuresTM Versus Bandaging for Venous Ulcers Recruiting NCT02790593 Phase 4
11 Flexitouch Compression System for Venous Stasis Ulcer Terminated NCT00534937 Phase 4
12 Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide Terminated NCT02512601 Phase 4 Sulodexide
13 Flexitouch Treatment for Venous Ulcers Terminated NCT00847002 Phase 4
14 Pulsed Electromagnetic Fields (PEMF) and Post-Axillary Surgery Morbidity Terminated NCT01255631 Phase 4
15 Treatment Trial for Post-Thrombotic Syndrome Unknown status NCT00633971 Phase 3
16 Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT) Unknown status NCT00421538 Phase 3 nadroparine calcium;Placebo
17 The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome Completed NCT00143598 Phase 3
18 Evaluation of a Venous-Return Assist Device (Venowave) to Treat Post-Thrombotic Syndrome: A Randomized Controlled Trial Completed NCT00182208 Phase 3
19 Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial Completed NCT01615705 Phase 3
20 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Completed NCT00790335 Phase 3 Recombinant tissue plasminogen activator (rt-PA)
21 Full-Leg vs Below-Knee Elastic Stockings for Prevention of the Post-Thrombotic Syndrome Completed NCT00426075 Phase 3
22 Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities Completed NCT00628576 Phase 3 unfractionated heparin;Tinzaparin (Leo)
23 Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2 Completed NCT01737762 Phase 3
24 Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers Completed NCT01656889 Phase 3
25 Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers Completed NCT00909870 Phase 3
26 DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT. Recruiting NCT00970619 Phase 3
27 Evaluation of the Duration of Therapy for Thrombosis in Children Recruiting NCT00687882 Phase 3
28 Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Recruiting NCT02197416 Phase 3 dabigatran etexilate
29 Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial Not yet recruiting NCT02767232 Phase 3 Recombinant tissue plasminogen activator (rt-PA);Standard Anticoagulation Therapy
30 A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Venous Leg Ulcers Not yet recruiting NCT02312518 Phase 2, Phase 3
31 EVENT: Hydrotherapy and Deep Venous Thrombosis Terminated NCT00348907 Phase 3 thermal cure;late thermal cure
32 Safety And Efficacy Of Topical Platelet Rich Plasma And Thrombin Coagulum Terminated NCT02802995 Phase 3 PRP/thrombin mixture
33 Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers Terminated NCT01853384 Phase 3
34 Clot Dissolving Treatment for Blood Clots in the Lungs Terminated NCT00680628 Phase 3 Tenecteplase + Enoxaparin;0.9% Saline + Enoxaparin
35 Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients Withdrawn NCT00912483 Phase 3
36 Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery Withdrawn NCT01474902 Phase 3 Enoxaparin
37 The Use of Intermittent Pneumatic Compression Device for Symptomatic Relief in Patients With Post Thrombotic Syndrome Unknown status NCT01637428 Phase 2
38 Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study Unknown status NCT02128178 Phase 1, Phase 2 Enoxaparin 40 mg 2 hours before arm;Enoxaparin 40 mg 12 hours before arm
39 Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers Completed NCT00832091 Phase 2 Thymosin Beta 4;Placebo
40 Dose Finding Study of HP802-247 in Venous Leg Ulcers Completed NCT00852995 Phase 2
41 The Effect of the Cosmetic Cream NMBM on Leg Ulcers - a Pilot Study Completed NCT01770509 Phase 1, Phase 2
42 The Efficacy of Venavine Intensive® on the Quality of Life in Females With Chronic Venous Insufficiency Completed NCT02498327 Phase 2
43 Allogeneic ABCB5-positive Stem Cells for Treatment of CVU Recruiting NCT03257098 Phase 1, Phase 2
44 Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers Recruiting NCT02742844 Phase 1, Phase 2
45 Statin Use in Patients With Acute VTE Recruiting NCT02331095 Phase 1, Phase 2 Atorvastatin;Warfarin
46 StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study Recruiting NCT02679664 Phase 2 Rosuvastatin
47 Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-related Lymphedema Recruiting NCT02946021 Phase 1, Phase 2 NIRFLI with ICG
48 Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence Recruiting NCT02626156 Phase 2
49 Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers Terminated NCT00613808 Phase 2 Nitric Oxide 200ppm Group B
50 Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers Terminated NCT00545298 Phase 2 Nitric Oxide - same dose 6 wks;Nitric Oxide modified treatment

Search NIH Clinical Center for Post-Thrombotic Syndrome

Cochrane evidence based reviews: postphlebitic syndrome

Genetic Tests for Post-Thrombotic Syndrome

Anatomical Context for Post-Thrombotic Syndrome

MalaCards organs/tissues related to Post-Thrombotic Syndrome:

38
Skin, Testes, Bone, Lung, Heart, Brain, Endothelial

Publications for Post-Thrombotic Syndrome

Articles related to Post-Thrombotic Syndrome:

(show top 50) (show all 108)
# Title Authors Year
1
Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. ( 29217387 )
2018
2
ABO blood group and the risk of post-thrombotic syndrome. ( 29387976 )
2018
3
A Summation Analysis of Compliance and Complications of Compression Hosiery for Patients with Chronic Venous Disease or Post-thrombotic Syndrome. ( 29329662 )
2018
4
Treatment of Femoral Vein Obstruction Concomitant with Iliofemoral Stenting in Patients with Severe Post-thrombotic Syndrome. ( 29292209 )
2018
5
Stockings to prevent post-thrombotic syndrome-where are we now? ( 29304324 )
2018
6
Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. ( 29324334 )
2018
7
Endophlebectomy of the common femoral vein and arteriovenous fistula creation as adjuncts to venous stenting for post-thrombotic syndrome. ( 28221670 )
2017
8
Diagnostic scales for the post-thrombotic syndrome. ( 29126608 )
2017
9
Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. ( 28692839 )
2017
10
Compression therapy for prevention of post-thrombotic syndrome. ( 28950030 )
2017
11
Epidemiology of the post-thrombotic syndrome. ( 28844444 )
2017
12
Post-thrombotic syndrome in children. ( 28811041 )
2017
13
Prevention and treatment of the post-thrombotic syndrome. ( 28736157 )
2017
14
Post thrombotic syndrome following deep vein thrombosis in paediatric patients. ( 28121229 )
2017
15
The importance of post thrombotic syndrome as an outcome after deep venous thrombosis: A survey of Canadian thrombosis clinicians. ( 28942356 )
2017
16
One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. ( 27245485 )
2016
17
The Treatment of Post-Thrombotic Syndrome. ( 28098065 )
2016
18
The post-thrombotic syndrome. ( 27913509 )
2016
19
Effect of compression stockings on post thrombotic syndrome in patients with deep vein thrombosis: a meta-analysis of randomised controlled trials. ( 27264039 )
2016
20
Deep vein thrombosis resolution, recurrence and post-thrombotic syndrome: a prospective observational study protocol. ( 27651905 )
2016
21
Predictors of the post-thrombotic syndrome and their effect on the therapeutic management of deep vein thrombosis. ( 27639012 )
2016
22
Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. ( 27247235 )
2016
23
Clot structure and fibrinolytic potential in patients with post thrombotic syndrome. ( 26589270 )
2016
24
Prevention of the Post-Thrombotic Syndrome. ( 27311456 )
2016
25
High rate of inter-observer agreement between professional-rated scores of the Villalta scale for the assessment of the post-thrombotic syndrome. ( 27392138 )
2016
26
Stockings to prevent post-thrombotic syndrome. ( 27245828 )
2016
27
The role of inflammation in post-thrombotic syndrome after pregnancy-related deep vein thrombosis: A population-based, cross-sectional study. ( 26826503 )
2016
28
Systematic Review and Meta-Analysis of Utility of Graduated Compression Stockings in Prevention of Post-Thrombotic Syndrome. ( 27026391 )
2016
29
Relationship between development of post-thrombotic syndrome and serial ultrasound, D-dimer, and factor VIII activity after a first deep venous thrombosis. ( 26946892 )
2016
30
Post Thrombotic Syndrome. ( 27628001 )
2016
31
Statins for the prevention of post-thrombotic syndrome in patients with deep vein thrombosis. Comment on San Norberto et al, p. 133 - 140. ( 27058793 )
2016
32
Predictors for the development of post-thrombotic syndrome in patients with primary lower limb deep venous thrombosis: A case-control study. ( 27083699 )
2016
33
Collateral circulation in pediatric post-thrombotic syndrome. ( 27404004 )
2016
34
Pediatric post-thrombotic syndrome in children: Toward the development of a new diagnostic and evaluative measurement tool. ( 27393923 )
2016
35
Understanding the barriers in compliance to elastic compression garments in the treatment of pediatric post-thrombotic syndrome: A qualitative study. ( 27318248 )
2016
36
Toll-like receptor 9 gene expression in the post-thrombotic syndrome, residual thrombosis and recurrent deep venous thrombosis: A case-control study. ( 26938157 )
2016
37
Impact of optimal anticoagulation therapy on chronic venous ulcer healing in thrombophilic patients with post-thrombotic syndrome. ( 27974007 )
2016
38
Oral anticoagulants, effect on thrombus resolution and post-thrombotic syndrome. ( 26916765 )
2016
39
Time taken to the maximum increase in the oxygenated hemoglobin level in calf muscle as a predictor of mild and moderate post-thrombotic syndrome. ( 27638999 )
2016
40
Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. ( 26853645 )
2016
41
Post-thrombotic syndrome. ( 27209458 )
2016
42
Novel perspectives on diagnosis and clinical significance of the post-thrombotic syndrome in children. ( 27677803 )
2016
43
Post-thrombotic syndrome and other outcomes of lower extremity deep vein thrombosis in children. ( 27474755 )
2016
44
Post-thrombotic syndrome and the risk of subsequent recurrent thromboembolism. ( 26986754 )
2016
45
Guidance for the prevention and treatment of the post-thrombotic syndrome. ( 26780743 )
2016
46
Efficacy of compression stockings in preventing post-thrombotic syndrome in patients with deep venous thrombosis: a systematic review and metaanalysis. ( 27058800 )
2016
47
Outcomes of Stent Placement for Chronic Occlusion of a Filter-bearing Inferior Vena Cava in Patients with Severe Post-thrombotic Syndrome. ( 27751714 )
2016
48
Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular BehAset's disease. ( 27318049 )
2016
49
Inter-rater agreement between professional-rated and patient-rated scores of the Villalta scale for evaluation of the post-thrombotic syndrome. ( 27058275 )
2016
50
Efficacy of compression for the prevention of post-thrombotic syndrome: an unsolved clinical conundrum Comment on Burgstaller et al, p. 141 - 147. ( 27058794 )
2016

Variations for Post-Thrombotic Syndrome

Expression for Post-Thrombotic Syndrome

Search GEO for disease gene expression data for Post-Thrombotic Syndrome.

Pathways for Post-Thrombotic Syndrome

Pathways related to Post-Thrombotic Syndrome according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.06 F2 F5 F8 SERPINC1 SERPINE1
2
Show member pathways
12.72 CCL2 IL6 SERPINE1 TLR9
3
Show member pathways
12.6 F2 F5 F8 SERPINC1
4
Show member pathways
12.56 CCL2 ICAM1 IL6 TLR9
5
Show member pathways
12.29 CCL2 IL6 SERPINE1 TLR9
6
Show member pathways
11.99 CCL2 F2 ICAM1 IL6 SERPINE1
7 11.83 CCL2 ICAM1 SERPINE1 TLR9
8 11.8 CCL2 ICAM1 IL6
9 11.77 CCL2 ICAM1 IL6
10 11.73 CCL2 ICAM1 IL6
11 11.64 CCL2 ICAM1 IL6
12 11.62 CCL2 ICAM1 IL6 SERPINE1
13
Show member pathways
11.56 F2 F5 F8 SERPINC1 SERPINE1
14 11.47 ICAM1 IL6 TLR9
15 11.32 CCL2 ICAM1 IL6
16 11.16 F2 F5 F8 SERPINC1 SERPINE1
17 11.15 ICAM1 IL6 TLR9
18 11.15 CCL2 ICAM1 IL6 TLR9
19 11.13 CCL2 IL6
20 10.94 CCL2 F2 ICAM1
21 10.76 CCL2 ICAM1

GO Terms for Post-Thrombotic Syndrome

Cellular components related to Post-Thrombotic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 CCL2 F2 F5 F8 IL6 SERPINC1
2 platelet alpha granule lumen GO:0031093 9.43 F5 F8 SERPINE1
3 endoplasmic reticulum lumen GO:0005788 9.35 F2 F5 F8 IL6 SERPINC1
4 COPII-coated ER to Golgi transport vesicle GO:0030134 9.32 F5 F8
5 extracellular space GO:0005615 9.28 CCL2 F2 F5 F8 ICAM1 IL6

Biological processes related to Post-Thrombotic Syndrome according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.84 CCL2 F2 IL6 SERPINE1
2 ER to Golgi vesicle-mediated transport GO:0006888 9.77 F2 F5 F8
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.73 ICAM1 IL6 TLR9
4 regulation of cell shape GO:0008360 9.72 CCL2 F2 ICAM1
5 platelet degranulation GO:0002576 9.67 F5 F8 SERPINE1
6 platelet activation GO:0030168 9.65 F2 F8 IL6
7 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.62 ICAM1 SERPINE1
8 cellular protein metabolic process GO:0044267 9.62 F2 F5 IL6 SERPINC1
9 negative regulation of endothelial cell apoptotic process GO:2000352 9.61 ICAM1 SERPINE1
10 positive regulation of interleukin-8 production GO:0032757 9.61 SERPINE1 TLR9
11 regulation of blood coagulation GO:0030193 9.6 F2 SERPINC1
12 fibrinolysis GO:0042730 9.58 F2 SERPINE1
13 positive regulation of chemokine production GO:0032722 9.58 IL6 TLR9
14 defense response to Gram-negative bacterium GO:0050829 9.58 IL6 SERPINE1 TLR9
15 blood coagulation, intrinsic pathway GO:0007597 9.57 F2 F8
16 blood coagulation GO:0007596 9.56 F2 F5 F8 SERPINC1
17 positive regulation of blood coagulation GO:0030194 9.52 F2 SERPINE1
18 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.51 CCL2 TLR9
19 negative regulation of fibrinolysis GO:0051918 9.46 F2 SERPINE1
20 acute inflammatory response to antigenic stimulus GO:0002438 9.43 ICAM1 SERPINC1
21 positive regulation of STAT protein import into nucleus GO:2000366 9.37 F2 IL6
22 acute-phase response GO:0006953 9.33 F2 F8 IL6
23 cellular response to lipopolysaccharide GO:0071222 9.26 CCL2 ICAM1 IL6 SERPINE1
24 hemostasis GO:0007599 8.92 F2 F5 F8 SERPINC1

Sources for Post-Thrombotic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....